Beerse, Belgium (ots/PRNewswire) - - Janssen presents one-year data from continued Phase 2 lupus study during plenary session at 2018 American College of Rheumatology (ACR) / Association for Rheumatology Health Professionals (ARHP) Annual Meeting The Janssen Pharmaceutical Companies of Johnson & Johnson today ...
Beerse, Belgium (ots/PRNewswire) - - One-year results from the Phase 2 study evaluating STELARA® (ustekinumab) in patients with active systemic lupus erythematosus featured in a plenary presentation - 13 presentations from approved and pipeline products provide real-world treatment and disease insights across ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE ONLY The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that ten company-sponsored abstracts will be presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, Netherlands being held on 13-16 June. Data from the ...
Cork, Ireland (ots/PRNewswire) - - Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir. The ongoing phase II ...
Beerse, Belgium (ots/PRNewswire) - Janssen announces results of pan-European research which shows that a third of psychiatrists (34%) delay conversations about the full range of treatment options with their patients living with schizophrenia. The 'Open Minds' survey, conducted among 347 psychiatrists across eight ...
Raritan, New Jersey (ots/PRNewswire) - New approach for early treatment and interception of HPV-induced cancers Janssen Pharmaceuticals, Inc. (Janssen) announced today that the company has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN® technology, ...
London (ots/PRNewswire) - A new report on tuberculosis (TB) published today by The Economist Intelligence Unit (EIU) investigates the increasing health challenges posed by TB and calls for new ways to improve the effectiveness of the global response to this pandemic.[1] The report supported by Janssen and titled ...
Beerse, Belgium (ots/PRNewswire) - New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide 'Tackling hepatitis C: Moving towards an integrated policy approach', a report published by The Economist Intelligence Unit (EIU) today reveals that many ...
Titusville, New Jersey (ots/PRNewswire) - Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A. VX-787 is an investigational ...
Beerse, Belgium (ots/PRNewswire) - /NOT INTENDED FOR UK MEDIA/ Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of monotherapy ibrutinib showed continued ...
Beerse, Belgium (ots/PRNewswire) - /NOT INTENDED FOR UK MEDIA/ Phase 3 data (Abstract LBA7008) featured in the official press programme of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine Data from the international, multicentre ...
Beerse, Belgium (ots/PRNewswire) - - Research in haematological malignancies features VELCADE(R), siltuximab, ibrutinib and daratumumab - Note: This release corresponds to EHA abstracts S1345, P958, P957, P369, P353, P960, P1211, P1209, P461, P356, P350, P434, P109 Janssen Pharmaceutica NV announced data related to ...
Beerse, Belgium (ots/PRNewswire) - -- Addressing chronic diseases key to sustainable healthcare reform in Europe Janssen Pharmaceutica NV (Janssen) has commissioned a new report based on independent research by The Swedish Institute of Health Economics[1] presented alongside the 2014 EU Summit on Chronic Diseases in Brussels today. The 'Access to high-quality oncology ...
Beerse, Belgium (ots/PRNewswire) - - OPTIMIZE study results presented at EASL show similar sustained virological response (SVR12) rates in patients with fibrosis or cirrhosis receiving an INCIVO(R)(telaprevir) combination treatment twice daily versus every eight hours - Janssen Infectious Diseases-Diagnostics BVBA ...
Boston, Massachusetts (ots/PRNewswire) - - Study presented at American Association for the Study of Liver Diseases 2012 shows high sustained virological response (SVR) in HCV/HIV co-infected patients receiving INCIVO(R) (telaprevir)-based regimen - Janssen Infectious Diseases-Diagnostics BVBA (Janssen) today ...
Beerse, Belgium (ots/PRNewswire) - NOT INTENDED FOR US JOURNALISTS - OPTIMIZE study results to be presented in late-breaking poster presentation at the American Association for the Study of Liver Diseases (AASLD) 2012 show non-inferior sustained virological response (SVR12) rates in previously untreated genotype-1 ...
Beerse, Belgium And Raritan, New Jersey (ots/PRNewswire) - ? Simultaneous Submissions Based on Data from Pre-chemo Prostate Cancer Study Janssen-Cilag International NV announced today it has submitted a type II variation to the European Medicines Agency (EMA) for ZYTIGA(R); simultaneously, Janssen Research & ...
Philadelphia (ots/PRNewswire) - Canagliflozin Provides Greater Reduction of A1C Levels in Adults with Type 2 Diabetes in 52-Week Head-to-Head Studies Compared to Sitagliptin and Glimepiride Janssen Research & Development, LLC (Janssen) presented results from five Phase 3 clinical studies evaluating canagliflozin in ...
Barcelona, Spain (ots/PRNewswire) - - Retrospective sub-analyses from ADVANCE, ILLUMINATE and REALIZE Phase 3 studies will be presented at European Association for the Study of the Liver (EASL) 2012 - Janssen Pharmaceutica NV (Janssen) will present new data for INCIVO (telaprevir) from Phase 3 retrospective ...
Chicago and Beerse, Belgium (ots/PRNewswire) - - Data From DACO-016 Trial at 2011 American Society of Clinical Oncology Annual Meeting - NB: Data in this release corresponds to ASCO abstract 6504 Data from the DACO-016 trial of DACOGEN(R) (decitabine) presented today at the 2011 Annual Meeting of the American ...